Literature DB >> 20340136

Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.

Heather A McKenzie1, Carina Fung, Therese M Becker, Mal Irvine, Graham J Mann, Richard F Kefford, Helen Rizos.   

Abstract

Inherited mutations affecting the INK4a/ARF locus (CDKN2A) are associated with melanoma susceptibility in 40% of multiple case melanoma families. Over 60 different germline INK4a/ARF mutations have been detected in more than 190 families worldwide. The majority of these alterations are missense mutations affecting p16(INK4a), and only 25% of these have been functionally assessed. There is therefore a need for an accurate and rapid assay to determine the functional significance of p16(INK4a) mutations. We reviewed the performance of several in vivo functional assays that measure critical aspects of p16(INK4a) function, including subcellular location, CDK binding and cell cycle inhibition. In this report the function of 28 p16(INK4a) variants, many associated with melanoma susceptibility were compared. We show that assessment of CDK4 binding and subcellular localization can accurately and rapidly determine the functional significance of melanoma-associated p16(INK4a) mutations. p16(INK4a)-CDK6 binding affinity was unhelpful, as no disease-associated mutation showed reduced CDK6 affinity while maintaining the ability to bind CDK4. Likewise, in silico analyses did not contribute substantially, with only 12 of 25 melanoma-associated missense variants consistently predicted as deleterious. The ability to determine variant functional activity accurately would identify disease-associated mutations and facilitate effective genetic counselling of individuals at high risk of melanoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20340136     DOI: 10.1002/humu.21245

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  11 in total

Review 1.  Clinical applications of melanoma genetics.

Authors:  Michele Gabree; Devanshi Patel; Linda Rodgers
Journal:  Curr Treat Options Oncol       Date:  2014-06

2.  Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma.

Authors:  Christopher Abdullah; Xiaolei Wang; Dorothea Becker
Journal:  Cell Cycle       Date:  2011-03-15       Impact factor: 4.534

3.  Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations.

Authors:  Thomas V O Hansen; Lars Jønson; Ane Y Steffensen; Mette K Andersen; Susanne Kjaergaard; Anne-Marie Gerdes; Bent Ejlertsen; Finn C Nielsen
Journal:  Fam Cancer       Date:  2011-06       Impact factor: 2.375

4.  A novel CDKN2A variant (p16L117P ) in a patient with familial and multiple primary melanomas.

Authors:  Christopher Li; Tong Liu; Bin Liu; Rolando Hernandez; Julio C Facelli; Douglas Grossman
Journal:  Pigment Cell Melanoma Res       Date:  2019-05-03       Impact factor: 4.693

5.  A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.

Authors:  Isaac P Horn; David L Marks; Amanda N Koenig; Tara L Hogenson; Luciana L Almada; Lauren E Goldstein; Paola A Romecin Duran; Renzo Vera; Anne M Vrabel; Gaofeng Cui; Kari G Rabe; William R Bamlet; Georges Mer; Hugues Sicotte; Cheng Zhang; Hu Li; Gloria M Petersen; Martin E Fernandez-Zapico
Journal:  J Biol Chem       Date:  2021-04-03       Impact factor: 5.157

Review 6.  Interplay between small and long non-coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces.

Authors:  Mattia Riefolo; Elisa Porcellini; Emi Dika; Elisabetta Broseghini; Manuela Ferracin
Journal:  Mol Oncol       Date:  2018-12-20       Impact factor: 6.603

7.  Loss-of-Function Mutations in the Cell-Cycle Control Gene CDKN2A Impact on Glucose Homeostasis in Humans.

Authors:  Aparna Pal; Thomas P Potjer; Soren K Thomsen; Hui Jin Ng; Amy Barrett; Raphael Scharfmann; Tim J James; D Timothy Bishop; Fredrik Karpe; Ian F Godsland; Hans F A Vasen; Julia Newton-Bishop; Hanno Pijl; Mark I McCarthy; Anna L Gloyn
Journal:  Diabetes       Date:  2015-11-05       Impact factor: 9.461

8.  The specificity and patterns of staining in human cells and tissues of p16INK4a antibodies demonstrate variant antigen binding.

Authors:  Magdalena Sawicka; Jeffrey Pawlikowski; Stephen Wilson; Dudley Ferdinando; Hong Wu; Peter David Adams; David Andrew Gunn; William Parish
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

9.  Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.

Authors:  Noah C Jenkins; Jae Jung; Tong Liu; Megan Wilde; Sheri L Holmen; Douglas Grossman
Journal:  J Invest Dermatol       Date:  2012-11-29       Impact factor: 8.551

10.  Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report.

Authors:  Vallari Shah; Kevin D Boyd; Richard S Houlston; Martin F Kaiser
Journal:  BMC Cancer       Date:  2017-11-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.